It is therefore useful to assess patients’ mutational status for prognostic purposes, and crucial to the choice of new target treatments such as the now-approved tyrosine kinase cabozantinib (3, 4) or the highly selective RET inhibitor pralsetinib currently being trialed for use against MTC (5). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.